AR126005A1 - Composiciones de psilocibina, métodos de fabricación y métodos de uso de las mismas - Google Patents
Composiciones de psilocibina, métodos de fabricación y métodos de uso de las mismasInfo
- Publication number
- AR126005A1 AR126005A1 ARP220101430A ARP220101430A AR126005A1 AR 126005 A1 AR126005 A1 AR 126005A1 AR P220101430 A ARP220101430 A AR P220101430A AR P220101430 A ARP220101430 A AR P220101430A AR 126005 A1 AR126005 A1 AR 126005A1
- Authority
- AR
- Argentina
- Prior art keywords
- psilocybin
- composition
- weight
- methods
- approximately
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 8
- QVDSEJDULKLHCG-UHFFFAOYSA-N psilocybin Chemical compound C1=CC(OP(O)(O)=O)=C2C(CCN(C)C)=CNC2=C1 QVDSEJDULKLHCG-UHFFFAOYSA-N 0.000 title abstract 8
- 238000000034 method Methods 0.000 title abstract 3
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- QKTAAWLCLHMUTJ-UHFFFAOYSA-N psilocybin Chemical compound C1C=CC(OP(O)(O)=O)=C2C(CCN(C)C)=CN=C21 QKTAAWLCLHMUTJ-UHFFFAOYSA-N 0.000 abstract 6
- 239000008194 pharmaceutical composition Substances 0.000 abstract 5
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 2
- 208000020401 Depressive disease Diseases 0.000 abstract 1
- 208000019022 Mood disease Diseases 0.000 abstract 1
- 230000007423 decrease Effects 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 239000000314 lubricant Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
La presente divulgación proporciona composiciones farmacéuticas que comprenden una cantidad terapéuticamente eficaz de psilocibina y uno o más excipientes farmacéuticamente aceptables. También se revelan los métodos de fabricación de dichas composiciones y uso de las mismas en el tratamiento de trastornos depresivos. Reivindicación 1: Una composición farmacéutica caracterizada porque comprende: una cantidad terapéuticamente eficaz de psilocibina; y uno o más excipientes farmacéuticamente aceptables, en la que, después del almacenamiento de la composición a 40ºC y el 75% de humedad relativa durante un mes, la potencia de la psilocibina en la composición disminuye en menos del 5% y el balance másico de la psilocibina y las sustancias relacionadas es superior al 97%. Reivindicación 4: La composición farmacéutica de una cualquiera de las reivindicaciones 1 - 3, caracterizada porque la composición comprende: a) aproximadamente el 85 - 99 % en peso de un diluyente; y b) aproximadamente el 0,5 - 2,0 % en peso de un lubricante. Reivindicación 5: La composición farmacéutica de una cualquiera de las reivindicaciones 1 - 4, caracterizada porque la composición comprende aproximadamente el 1% - 10% en peso de psilocibina. Reivindicación 6: La composición farmacéutica de una cualquiera de las reivindicaciones 1 - 4, caracterizada porque la composición comprende aproximadamente el 1% - 15 % en peso de psilocibina. Reivindicación 52: Un método de tratamiento de un trastorno del estado de ánimo, caracterizado porque comprende administrar una cantidad terapéuticamente eficaz de la composición de una cualquiera de las reivindicaciones 1 - 38 y 51.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163168055P | 2021-03-30 | 2021-03-30 | |
| PCT/EP2022/058483 WO2022207746A1 (en) | 2021-03-30 | 2022-03-30 | Psilocybin compositions, methods of making and methods of using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR126005A1 true AR126005A1 (es) | 2023-08-30 |
Family
ID=81448508
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220100771A AR125250A1 (es) | 2021-03-30 | 2022-03-30 | Composiciones de psilocibina, procedimientos de fabricación y procedimientos de uso de las mismas |
| ARP220101430A AR126005A1 (es) | 2021-03-30 | 2022-05-31 | Composiciones de psilocibina, métodos de fabricación y métodos de uso de las mismas |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220100771A AR125250A1 (es) | 2021-03-30 | 2022-03-30 | Composiciones de psilocibina, procedimientos de fabricación y procedimientos de uso de las mismas |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP4312995A1 (es) |
| JP (1) | JP2024512983A (es) |
| KR (1) | KR20230175186A (es) |
| CN (1) | CN117460498A (es) |
| AR (2) | AR125250A1 (es) |
| AU (1) | AU2022246987A1 (es) |
| BR (1) | BR112023018472A2 (es) |
| CA (1) | CA3210649A1 (es) |
| CO (1) | CO2023013050A2 (es) |
| IL (1) | IL305435A (es) |
| TW (1) | TW202304466A (es) |
| WO (1) | WO2022207746A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| WO2020212952A1 (en) | 2019-04-17 | 2020-10-22 | Compass Pathfinder Limited | Treatment of depression and other various disorders with psilocybin |
| WO2023114097A1 (en) | 2021-12-13 | 2023-06-22 | Compass Pathfinder Limited | Psilocybin and an adjunctive serotonin reuptake inhibitor for use in the treatment of treatment-resistant depression |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1861427B1 (en) | 2005-03-23 | 2012-08-08 | BPSI Holdings, LLC. | Agglomerated starch compositions |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| KR20210134313A (ko) * | 2019-01-30 | 2021-11-09 | 다이아몬드 테라퓨틱스 인크. | 심리적, 인지적, 행동적 및/또는 기분 장애의 치료를 위한 5ht 수용체 아고니스트를 포함하는 조성물 및 방법 |
| WO2020212952A1 (en) | 2019-04-17 | 2020-10-22 | Compass Pathfinder Limited | Treatment of depression and other various disorders with psilocybin |
| US11766445B2 (en) * | 2019-07-18 | 2023-09-26 | Concept Matrix Solutions | Oral soft gel capsule containing psychedelic compound |
-
2022
- 2022-03-30 KR KR1020237032066A patent/KR20230175186A/ko unknown
- 2022-03-30 EP EP22719872.8A patent/EP4312995A1/en active Pending
- 2022-03-30 JP JP2023559739A patent/JP2024512983A/ja active Pending
- 2022-03-30 TW TW111112319A patent/TW202304466A/zh unknown
- 2022-03-30 CA CA3210649A patent/CA3210649A1/en active Pending
- 2022-03-30 AR ARP220100771A patent/AR125250A1/es unknown
- 2022-03-30 BR BR112023018472A patent/BR112023018472A2/pt unknown
- 2022-03-30 IL IL305435A patent/IL305435A/en unknown
- 2022-03-30 AU AU2022246987A patent/AU2022246987A1/en active Pending
- 2022-03-30 WO PCT/EP2022/058483 patent/WO2022207746A1/en active Application Filing
- 2022-03-30 CN CN202280022409.6A patent/CN117460498A/zh active Pending
- 2022-05-31 AR ARP220101430A patent/AR126005A1/es unknown
-
2023
- 2023-09-29 CO CONC2023/0013050A patent/CO2023013050A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4312995A1 (en) | 2024-02-07 |
| CO2023013050A2 (es) | 2023-10-19 |
| CN117460498A (zh) | 2024-01-26 |
| JP2024512983A (ja) | 2024-03-21 |
| KR20230175186A (ko) | 2023-12-29 |
| IL305435A (en) | 2023-10-01 |
| AR125250A1 (es) | 2023-06-28 |
| BR112023018472A2 (pt) | 2023-10-10 |
| TW202304466A (zh) | 2023-02-01 |
| WO2022207746A1 (en) | 2022-10-06 |
| AU2022246987A1 (en) | 2023-09-07 |
| CA3210649A1 (en) | 2022-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR126005A1 (es) | Composiciones de psilocibina, métodos de fabricación y métodos de uso de las mismas | |
| CR20170411A (es) | Composiciones farmacéuticas que comprenden n-(3,5-dimetoxifenil)-n-(1-metiletil)-n-[3-(1-metil-1h-pirazol-4-il-quin oxalin-6-il]etano-1,2-diamina | |
| EA201990820A1 (ru) | Способы лечения митохондриальных и метаболических нарушений | |
| BR112023020442A2 (pt) | Inibidor da protease 1 específica de ubiquitina (usp1) | |
| BR112022022578A2 (pt) | Novas composições e métodos de tratar doença covid-19 | |
| EA202191239A1 (ru) | Соединения и их применение для лечения дефицита 1-антитрипсина | |
| EA202191188A1 (ru) | Бензамиды производных пиразолил-амино-пиримидинила, композиции на их основе и способы применения | |
| PH12021551232A1 (en) | Haloallylamine compounds and application thereof | |
| AR052062A1 (es) | Composicion y metodo para tratar el asma | |
| CO2021009186A2 (es) | Glutarato de 3-(1,2,3,6-tetrahidropiridin-2-il)piridina o un solvato farmacéuticamente aceptable del mismo | |
| EA202192322A1 (ru) | Фармацевтические составы | |
| CL2022002386A1 (es) | Compuestos de amino pirimidina fusionados | |
| BR112021020027A2 (pt) | Compostos, composições e métodos | |
| PH12019502652A1 (en) | 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases | |
| CL2023002871A1 (es) | Composiciones nasales que comprenden alcaftadina | |
| CO2023004420A2 (es) | Compuestos heterocíclicos como inhibidores del bromodominio cbp/ep300 | |
| EA202090827A1 (ru) | Пероральные композиции для лечения гастроэзофагеального рефлюкса | |
| EA202190966A1 (ru) | Пролекарства антагонистов cgrp | |
| CL2021000627A1 (es) | Composiciones farmacéuticas adecuadas para liberación articular y su uso en el tratamiento del dolor articular | |
| EA202193190A1 (ru) | Композиция, включающая придопидин и его аналог, для лечения болезни гентингтона и ее симптомов | |
| AR108792A1 (es) | Composiciones que comprenden timolol | |
| AR121376A1 (es) | Uso de análogos de ciclosporina para tratar la fibrosis | |
| EA202091320A1 (ru) | Местное применение диоксидина при инфекционно-воспалительных поражениях эпителия | |
| JOP20200233A1 (ar) | مثبطات إفراز بروتين أساسه تراي أزا سيكلو دوديكان سلفوناميد ('tcd') | |
| EA202092944A1 (ru) | Применение пероральных распадающихся таблеток рилузола для лечения заболеваний |